What is Regeneron's current financial status and outlook?

Regeneron continues to operate at a net loss, reflecting significant ongoing investment in research and development. However, revenues have grown substantially due to collaboration agreements, leading to a reduced net loss compared to the prior year. The company believes its current capital resources and anticipated funding from collaborations will sustain operations through at least 2012, but acknowledges the risks and potential need for future financing.

What are the key revenue drivers for Regeneron?

The primary revenue drivers for Regeneron are contract research and development revenues from its collaborations, particularly with sanofi-aventis (for aflibercept and antibody programs) and Bayer HealthCare (for VEGF Trap-Eye). Technology licensing revenue from agreements with AstraZeneca and Astellas also contributes significantly. ARCALYST product sales are beginning to contribute, though projected to be modest for 2008.

What is the status of Regeneron's product pipeline?

Regeneron has one marketed product, ARCALYST (rilonacept), for CAPS. Its late-stage clinical programs include aflibercept (VEGF Trap) for oncology, VEGF Trap-Eye for eye diseases, and ARCALYST for inflammatory diseases like gout. The company is also advancing its antibody programs, developed under the sanofi-aventis collaboration, into clinical trials.

Are there any significant risks associated with Regeneron's investments?

Yes, Regeneron holds a substantial amount of marketable securities ($376.5 million as of September 30, 2008). The company recognized impairment charges of $1.7 million and $2.3 million during the three and nine months ended September 30, 2008, respectively, due to declines in value considered other-than-temporary. The filing notes that the current economic environment increases the risk of further declines and potential material impairment charges.

REGN 10-Q Quarterly Report Q3 FY2008 — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. reported its financial results for the third quarter and nine months ended September 30, 2008. The company experienced a significant increase in total revenues, primarily driven by its collaborations with sanofi-aventis and Bayer HealthCare. While net losses decreased year-over-year due to this revenue growth, the company continues to invest heavily in research and development, leading to substantial operating expenses. ARCALYST (rilonacept) was launched commercially in March 2008 for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), with projected shipments of $10 million in 2008. The company also advanced its late-stage clinical programs for aflibercept (VEGF Trap) in oncology and VEGF Trap-Eye for eye diseases. Significant collaboration agreements, particularly with sanofi-aventis for antibody discovery and development, are central to Regeneron's strategy and funding. Despite revenue growth, the company remains in a cumulative loss position and continues to require substantial funding for its extensive R&D activities. Management anticipates sufficient capital to meet operating needs through at least 2012, but acknowledges the inherent risks and uncertainties in drug development and the potential need for future financing.

Key Highlights

1Total revenues increased significantly in Q3 2008 ($65.6M) and the first nine months of 2008 ($182.6M) compared to the prior year periods, driven by collaboration revenues from sanofi-aventis and Bayer HealthCare.
2Net loss for Q3 2008 was $21.1 million ($0.27/share), an improvement from $35.8 million ($0.54/share) in Q3 2007. Nine-month net loss was $51.2 million ($0.65/share), down from $92.5 million ($1.40/share) in the prior year.
3ARCALYST (rilonacept) was launched in March 2008 for CAPS, with projected 2008 shipments of $10 million.
4Research and development expenses increased substantially, reaching $73.8 million in Q3 2008 and $201.7 million for the first nine months, reflecting expanded R&D activities, particularly in antibody programs.
5The company repurchased $82.5 million of its 5.5% Convertible Senior Subordinated Notes due October 17, 2008, for $83.3 million during the first nine months of 2008.
6Marketable securities stood at $376.5 million at September 30, 2008, with $1.7 million and $2.3 million in impairment charges recognized for other-than-temporary declines in value during the three and nine months ended September 30, 2008, respectively.
7Regeneron anticipates that existing capital resources and collaboration funding will enable it to meet operating needs through at least 2012.

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q3 Ended Sep 30, 2008

Summary

Key Highlights

Frequently Asked Questions